GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine

The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new thera...

Full description

Bibliographic Details
Main Authors:	Ferro, Riccardo, Adamska, Aleksandra, Lattanzio, Rossano, Mavrommati, Ioanna, Edling, Charlotte E., Ahmad Arifin, Syamsul, Fyffe, Chanse A., Sala, Gianluca, Sacchetto, L., Chiorino, Giovanna, De Laurenzi, Vincenzo, Piantelli, Mauro, Sansom, Owen, Maffucci, Tania, Falasca, Marco
Format:	Article
Language:	English English
Published:	Nature Publishing Group 2018
Subjects:	RM147 Administration of Drugs and Other Therapeutic Agents RM283 Endocrinotheraphy RM300 Drugs and their action
Online Access:	http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/1/65709_GPR55%20signalling%20promotes.pdf http://irep.iium.edu.my/65709/2/65709_GPR55%20signalling%20promotes_SCOPUS%20in%20press.pdf

id	iium-65709
recordtype	eprints
spelling	iium-657092018-09-20T06:02:24Z http://irep.iium.edu.my/65709/ GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine Ferro, Riccardo Adamska, Aleksandra Lattanzio, Rossano Mavrommati, Ioanna Edling, Charlotte E. Ahmad Arifin, Syamsul Fyffe, Chanse A. Sala, Gianluca Sacchetto, L. Chiorino, Giovanna De Laurenzi, Vincenzo Piantelli, Mauro Sansom, Owen Maffucci, Tania Falasca, Marco RM147 Administration of Drugs and Other Therapeutic Agents RM283 Endocrinotheraphy RM300 Drugs and their action The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+ (KPC) mouse model of PDAC significantly prolonged survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), survived nearly three times longer compared to mice treated with vehicle or GEM alone. Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage-dependent and independent growth, cell cycle progression, activation of mitogen-activated protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the tumour suppressor p53 regulates GPR55 protein expression through modulation of the microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD and GEM, both currently approved for medical use, might be tested in clinical trials as a novel promising treatment to improve PDAC patients’ outcome Nature Publishing Group 2018-07-30 Article PeerReviewed application/pdf en http://irep.iium.edu.my/65709/1/65709_GPR55%20signalling%20promotes.pdf application/pdf en http://irep.iium.edu.my/65709/2/65709_GPR55%20signalling%20promotes_SCOPUS%20in%20press.pdf Ferro, Riccardo and Adamska, Aleksandra and Lattanzio, Rossano and Mavrommati, Ioanna and Edling, Charlotte E. and Ahmad Arifin, Syamsul and Fyffe, Chanse A. and Sala, Gianluca and Sacchetto, L. and Chiorino, Giovanna and De Laurenzi, Vincenzo and Piantelli, Mauro and Sansom, Owen and Maffucci, Tania and Falasca, Marco (2018) GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene. p. 1. ISSN 0950-9232 E-ISSN 1476-5594 (In Press) https://www.nature.com/articles/s41388-018-0390-1 10.1038/s41388-018-0390-1
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English
topic	RM147 Administration of Drugs and Other Therapeutic Agents RM283 Endocrinotheraphy RM300 Drugs and their action
spellingShingle	RM147 Administration of Drugs and Other Therapeutic Agents RM283 Endocrinotheraphy RM300 Drugs and their action Ferro, Riccardo Adamska, Aleksandra Lattanzio, Rossano Mavrommati, Ioanna Edling, Charlotte E. Ahmad Arifin, Syamsul Fyffe, Chanse A. Sala, Gianluca Sacchetto, L. Chiorino, Giovanna De Laurenzi, Vincenzo Piantelli, Mauro Sansom, Owen Maffucci, Tania Falasca, Marco GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
description	The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+ (KPC) mouse model of PDAC significantly prolonged survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), survived nearly three times longer compared to mice treated with vehicle or GEM alone. Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage-dependent and independent growth, cell cycle progression, activation of mitogen-activated protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the tumour suppressor p53 regulates GPR55 protein expression through modulation of the microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD and GEM, both currently approved for medical use, might be tested in clinical trials as a novel promising treatment to improve PDAC patients’ outcome
format	Article
author	Ferro, Riccardo Adamska, Aleksandra Lattanzio, Rossano Mavrommati, Ioanna Edling, Charlotte E. Ahmad Arifin, Syamsul Fyffe, Chanse A. Sala, Gianluca Sacchetto, L. Chiorino, Giovanna De Laurenzi, Vincenzo Piantelli, Mauro Sansom, Owen Maffucci, Tania Falasca, Marco
author_facet	Ferro, Riccardo Adamska, Aleksandra Lattanzio, Rossano Mavrommati, Ioanna Edling, Charlotte E. Ahmad Arifin, Syamsul Fyffe, Chanse A. Sala, Gianluca Sacchetto, L. Chiorino, Giovanna De Laurenzi, Vincenzo Piantelli, Mauro Sansom, Owen Maffucci, Tania Falasca, Marco
author_sort	Ferro, Riccardo
title	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
title_short	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
title_full	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
title_fullStr	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
title_full_unstemmed	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
title_sort	gpr55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
publisher	Nature Publishing Group
publishDate	2018
url	http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/ http://irep.iium.edu.my/65709/1/65709_GPR55%20signalling%20promotes.pdf http://irep.iium.edu.my/65709/2/65709_GPR55%20signalling%20promotes_SCOPUS%20in%20press.pdf
first_indexed	2023-09-18T21:33:13Z
last_indexed	2023-09-18T21:33:13Z
_version_	1777412649114402816

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine

Similar Items